Navigation Links
Robert W. Lee, Ph.D. Joins Particle Sciences as Vice President of Pharmaceutical Development

BETHLEHEM, Pa., April 28 /PRNewswire/ -- Particle Sciences, Inc. today announced the appointment of Robert W. Lee, Ph.D. to the position of Vice President, Pharmaceutical Development.

Dr. Lee joins Particle Sciences following more than 17 years experience in pharmaceutical research and development of both therapeutic drugs and diagnostic imaging agents. Most recently, he served Novavax, Inc. as Vice President of Pharmaceutical Development. Prior to that, Dr. Lee held senior management positions at Lyotropic Therapeutics, Inc. and IMCOR Pharmaceutical Co. Dr. Lee is currently serving as a scientific advisor for NanoScan Imaging, LLC, and Savara Pharmaceutical.

From 1990 to 2002, Dr. Lee held various R&D positions within Sterling Winthrop Pharmaceuticals Research Division, NanoSystems, and elan Drug Delivery, Inc. His areas of expertise include Preformulation, drug delivery, formulation development, analytical sciences, sterile manufacturing, and technology evaluation and development. Dr. Lee was one of the founding members of NanoSystems, a drug delivery company focused on the formulation of water-insoluble drugs. He maintains strong academic ties, including an appointment as Adjunct Associate Professor of Pharmaceutical Chemistry at the University of Kansas in 1992, and serving as a reviewer for both the International Journal of Pharmaceutics and Journal of Pharmaceutical Sciences.

Dr. Mitchnick comments that "Robert brings a wealth of experience to the Particle Sciences team. His background fits perfectly with our continued focus on advanced delivery systems. Particle Sciences typically deals with difficult to solubilize API's and nanotechnology based systems. Rob has deep experience in these areas as well as in clinical trial manufacturing, another area in which Particle sciences is expanding."

Dr. Lee received a Ph.D. in Physical Bioorganic Chemistry under the direction of Professor Thomas C. Bruice from the University of California, Santa Barbara and B.Sc.'s in both Chemistry and Biology from the University of Washington. He is the author or co-author of 11 patents, 14 provisional and PCT patent applications, nine research articles, and three book chapters.

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.


Maureen Cochran


SOURCE Particle Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Chairman Robert Essner Announces June 27 Retirement
2. Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems
3. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
4. Hiemstra Appoints Robert C. Glines as Director of Business Development
5. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
6. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
7. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
8. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
9. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
10. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
11. Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts
Post Your Comments:
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015  Vigilant Solutions announces today that Mr. ... of Directors. --> --> ... from the partnership at TPG Capital, one of the ... $140 Billion in revenue.  He founded and led TPG,s ... TPG companies, from 1997 to 2013.  In his first ...
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
Breaking Biology News(10 mins):